삼성바이오로직스

From real-time monitoring to standardizing processes, Samsung Biologics is committed to minimizing downtime and delivering consistent product quality. Read our latest newsroom story to learn how we achieve seamless biopharmaceutical manufacturing through meticulous facility maintenance and optimized operations. Read more https://lnkd.in/g3sSbTGB #SamsungBiologics #cdmo #manufacturing #OperationalExcellence

As part of our continued commitment to technology innovation, Samsung Biologics leverages CDO platforms like S-AfuCHO™, S-OptiCharge™, and S-Tensify™ to enhance therapeutic efficacy and meet evolving industry needs. Get insights from this article on how we accelerate development, achieve the highest quality, and flexibly meet clients' goals. Read more: https://lnkd.in/gZqjSvbD #SamsungBiologics #drugdevelopment #cdmo

Ensuring viral safety in large-scale manufacturing requires a deep understanding of intricate factors that affect virus filter performance. In our latest article, we explore how shifts in air diffusion values impact virus clearance in multi-round housings as well as the key considerations for effective risk assessment. Read here: https://lnkd.in/eJ-a4wHt #SamsungBiologics #VirusFiltration #MSAT #Manufacturing #ScaleUp

While antibody-drug conjugates (ADC) are emerging as a promising class of anti-cancer treatment, access to effective therapeutic agents remains limited. In this webinar, we delve into the importance of choosing high-quality payloads in ADC development and how our novel payload technologies can support increased efficacy and safety. Register now: https://lnkd.in/e_NgyJXh #ADC #payloads #linker_technology #webinar 

We proactively stay ahead of industry expectations by delivering on our capacity expansion commitments down to the month. With a current total manufacturing capacity of 604 kL, we are continuously expanding our scope to grow with our clients and stay on track with their timelines: https://lnkd.in/gZgm3Wtr #SamsungBiologics #Commitment #OnTrack #Capacity

Recent innovations in intensified fed-batch (IFB) processing have led to substantial improvements in cell culture yields and scalability to support efficient biopharmaceutical production. Watch this webinar, where our upstream process development scientists discuss the latest advancements in IFB processing and how our S-Tensify™ platform ensures consistent quality and productivity. https://lnkd.in/gau_f2Wm #SamsungBiologics #drugdevelopment #celldensity #cellculture #CLD #FedBatch

As biologics manufacturing can present unique challenges, partnering with a CDMO service provider with expertise and readily available capacity is crucial for success. Register for the Outsourced Pharma Capacity Update presentation on October 22 at 2PM (ET), where John Gagliardi, Senior Director of CMO Sales, will share insights on our enhanced manufacturing capabilities including N-1 perfusion technology and expansion into ADC. Register now: https://lnkd.in/eYy3v5Mb #SamsungBiologics #cdmo #Manufacturability #Perfusion #DP

Samsung Biologics has signed a record-breaking manufacturing deal with an Asia-based pharmaceutical company, a reflection of trusted and sustainable partnerships with our clients to help save patients around the world. By leveraging our innovative biomanufacturing technologies and proven expertise, we will continue our commitment to delivering high-quality biomedicines to the global market. Read more: https://lnkd.in/gkEVyG9c #SamsungBiologics #cdmo #manufacturing #partnership #deal

From cell line development to IND submission, Samsung Biologics has a track record of bringing fusion proteins and other complex molecules to preclinical testing. Deep understanding of a molecule based on a robust in-house database assures clients of timely solutions. Read the latest Newsroom story to discover our CDO services: https://lnkd.in/e8RRsmhW #SamsungBiologics #CDMO #CDO #ComplexMolecules

While multispecifics can present challenges in manufacturing due to their elaborate molecular structure, Samsung Biologics offers strengths in agility, flexibility, operational excellence, technology innovation, and timely capacity expansions to support clients’ complex manufacturing needs. Unlock the potential of your multispecific antibodies with advanced manufacturing technologies. Read here: https://lnkd.in/gcXrt9w2 #SamsungBiologics #Multispecific #Manufacturing